Premenstrual Dysphoric Disorder (PMDD)

Author: Alana Cookman. Alana is a health researcher specializing in Women's Health within work contexts. She employs a systems-thinking approach to exploring health narratives. She has a rich background in social change and health system transformation. She's the primary author of this report, which was made under the support and sponsorship of Eleanor Taylor.

Introduction

This topic page presents findings from an exploratory research project. The primary aim was to illuminate and understand how women with Premenstrual Dysphoric Disorder (PMDD) use psilocybin (magic mushrooms or truffles). The research was prompted by the growing number of women seeking guidance on using psilocybin for PMDD on online platforms, like Reddit and Facebook, having exhausted other treatment options. This exploratory study is entirely independent and mirrors the grassroots efforts encountered in the research.

PMDD is a severe, often debilitating condition that goes far beyond typical premenstrual symptoms. Women with PMDD describe cyclical experiences of intense emotional and physical distress that can consume up to half of every month. Despite its severity, PMDD remains under-researched and frequently misdiagnosed. Many women spend years seeking answers before receiving a proper diagnosis, during which time the condition takes a profound toll on their relationships, careers, and overall wellbeing.

With limited effective treatment options available through conventional medicine, a growing community of women has begun exploring psilocybin as a potential way to manage their symptoms. This report captures their experiences, motivations, and outcomes through qualitative interviews, providing a foundation for future clinical investigation into this promising but understudied area.

Current Research Landscape

PMDD is now recognized in both the DSM-5# and the ICD-11# as a distinct clinical condition, lending it greater legitimacy after decades of dismissal. According to the International Association for Premenstrual Disorders (IAPMD)#, PMDD affects approximately 5.5% of menstruating women worldwide. The average age of diagnosis is 35, despite symptoms typically beginning much earlier, with an average of 8.6 years of symptoms before diagnosis#. The severity of the condition is underscored by the finding that 34% of those with PMDD have attempted suicide#, making it a critical area for therapeutic innovation.

Current first-line treatments include SSRIs and hormonal interventions such as oral contraceptives and GnRH agonists. While SSRIs can be effective for some women, a significant proportion do not respond adequately or experience intolerable side effects#. Hormonal treatments carry their own risk profiles, and for some women the only definitive medical solution offered is surgical menopause — a drastic and irreversible option. The Premenstrual Symptoms Screening Tool (PSST)# remains one of the primary diagnostic instruments, though diagnosis is still largely based on prospective symptom tracking over multiple cycles.

Several theoretical pathways suggest why psilocybin may be beneficial for PMDD. The most prominent involves serotonin receptor modulation: psilocybin acts primarily on the 5-HT2A receptor, the same serotonergic system implicated in PMDD pathophysiology. Research has shown that women with PMDD have altered serotonin sensitivity during the luteal phase#, and psilocybin's ability to modulate these receptors could offer a mechanism of action distinct from daily SSRIs. Additionally, the interaction between psychedelics and the hypothalamic-pituitary-gonadal (HPG) axis# may have implications for the hormonal sensitivity that characterizes PMDD.

Neuroplasticity is another key area of interest. Psilocybin has been shown to promote synaptogenesis and neural flexibility, which could help disrupt the rigid negative thought patterns and emotional reactivity experienced during the luteal phase. There is also a growing body of evidence linking PMDD to trauma and adverse childhood experiences#, with PTSD frequently comorbid with severe PMS and PMDD#. Given psilocybin's demonstrated efficacy in treating PTSD and trauma-related conditions, this connection provides further rationale for investigation. Epigenetic mechanisms and anti-inflammatory effects represent additional pathways worth exploring, as inflammatory markers have been found to be elevated in women with PMDD#.

Methodology

This study employed an exploratory qualitative approach, using semi-structured interviews to capture the lived experiences of women who have used psilocybin to manage PMDD symptoms. Eleven women were interviewed, recruited primarily via Reddit communities (r/PMDD and r/PsychedelicWomen). Thematic analysis was adapted from Braun and Clarke's reflexive thematic analysis framework#, allowing themes to emerge organically from the data rather than being imposed through a pre-existing framework.

Participants ranged in age from their mid-20s to mid-40s, representing diverse backgrounds and levels of experience with psilocybin. All had a confirmed or self-identified PMDD diagnosis and had used psilocybin at least once with the intention of addressing PMDD symptoms. The interviews covered their PMDD history, route to psilocybin, experiences with the substance, observed changes in symptoms and behaviour, and reflections on the broader cultural context of their condition.

The researcher maintained a reflexive journal throughout the process, acknowledging her own positionality and its potential influence on data interpretation. Given the sensitive and stigmatized nature of both PMDD and psilocybin use, particular care was taken to create a safe, non-judgmental interview environment. All participants provided informed consent and were assured of anonymity.

Key Findings

The PMDD Experience and Route to Psilocybin

Participants described PMDD as a condition that dominated their lives, with symptoms including severe mood swings, uncontrollable irritability and rage, suicidal ideation, extreme emotional sensitivity, and profound fatigue. The experience was consistently described as traumatic in its own right — a cyclical "bad trip" that eroded confidence, relationships, and sense of self. Many participants drew parallels between the dissociation and emotional overwhelm of PMDD episodes and descriptions of challenging psychedelic experiences.

Trauma emerged as a key component of participants' histories. The majority reported significant adverse experiences, including childhood abuse, sexual assault, and domestic violence. Several participants noted that their PMDD symptoms intensified after traumatic events, suggesting an interplay between trauma and hormonal sensitivity that warrants further investigation.

Diagnosis times were remarkably long, ranging from several years to over two decades. Participants described a gauntlet of misdiagnoses — bipolar disorder, borderline personality disorder, general anxiety — before finally identifying PMDD, often through their own research rather than clinical guidance. Self-advocacy was crucial throughout, with women reporting that they had to push back against dismissive healthcare providers repeatedly. As Tina Williams has documented#, the combination of medical gaslighting and inadequate treatment options drives many women toward self-directed exploration of alternatives like psilocybin.

Initial treatments prescribed by healthcare providers — primarily SSRIs and hormonal contraceptives — were reported as largely ineffective or accompanied by intolerable side effects. Several participants described gaining weight, losing libido, feeling emotionally "flattened," or experiencing worsened symptoms on these medications. The failure of conventional treatments, combined with limited access to specialized care, was the primary driver toward alternative exploration. Most participants discovered psilocybin through online communities where other women shared their experiences.

The Psilocybin Experiences

Approaches to psilocybin use were diverse across participants. Some engaged in regular microdosing protocols (sub-perceptual doses every few days), others used moderate doses (1-2.5 grams of dried mushrooms) every couple of months, and some undertook larger ceremonial or macrodoses (3.5 grams or more). The most commonly reported effective approach was moderate dosing every one to three months, which participants found provided meaningful symptom management with less disruption to daily life than larger doses.

Macro doses appeared to hold more transformative potential — participants who had larger experiences described profound shifts in perspective, emotional breakthroughs related to trauma, and lasting changes in self-concept. However, these experiences also carried increased risks, particularly when undertaken without adequate preparation, support, or in an unsuitable environment. Several participants reported challenging experiences with higher doses that required significant integration work afterward.

Preparation and intention-setting were consistently identified as important factors in the quality of the experience. Participants who approached psilocybin with clear therapeutic intentions and in supportive settings generally reported better outcomes. Fear of surrender — of letting go of control — was a common theme, particularly among women whose PMDD had made them feel chronically out of control. Learning to surrender within the psilocybin experience was described by several participants as itself therapeutic.

Timing of psilocybin use in relation to the menstrual cycle varied among participants. Some avoided the luteal phase entirely, finding that the emotional volatility of that period made for unpredictable or overwhelming experiences. Others deliberately chose different cycle phases for different types of sessions. A few participants reported no significant difference regardless of timing, though the majority expressed a preference for the follicular phase when they felt more emotionally stable.

Changes in Symptoms

The most consistently reported improvements were in the emotional and psychological symptoms of PMDD. Suicidal ideation — often the most terrifying aspect of the condition — was reported to diminish significantly or disappear entirely in the cycles following psilocybin use. Uncontrollable anger and rage, which many participants described as the most relationship-damaging symptom, was notably reduced. The so-called "hell week" — the period of most intense symptoms before menstruation — was reported to be eliminated or significantly shortened by most participants.

Several participants were able to reduce or discontinue antidepressant medications after incorporating psilocybin into their management approach, though this was always done gradually and with awareness of the risks. Relationship dynamics improved as emotional reactivity decreased, with partners and family members commenting on noticeable changes.

However, the benefits were not permanent or automatic. Symptom resurgence was reported when psilocybin sessions lapsed, during periods of high stress, or when significant life changes occurred. Participants were clear that psilocybin was one component of an ongoing management strategy — not a cure. Most combined psilocybin use with other practices including therapy, exercise, dietary changes, mindfulness, and community support. The need for continued, periodic use suggests that psilocybin's effects on PMDD may be more about ongoing symptom management than permanent resolution.

Increased Self-Awareness

One of the most profound and consistent themes was the role of psilocybin in facilitating deeper self-knowledge. Participants described gaining new insight into their emotional patterns, triggers, and the ways PMDD had shaped their identity and behaviour. This self-awareness extended beyond the acute psilocybin experience, with many reporting a sustained shift in their relationship with themselves.

A significant shift occurred from patterns of self-harm and self-punishment to self-care and self-compassion. Participants described psilocybin as helping them access feelings of acceptance and forgiveness — both toward themselves and others — that had felt inaccessible through talk therapy alone. There was a greater sense of permission to love and care for themselves, which many noted was a radical departure from the self-loathing that often accompanied PMDD episodes. The reduced need to self-harm and increased trust in their own bodies were described as among the most valuable changes.

Connection to Others

PMDD creates significant challenges around isolation and self-silencing. Participants described withdrawing from relationships during symptomatic periods, either to protect others from their irritability and rage or because the effort of social interaction felt impossible. Over time, this cyclical withdrawal eroded social connections and deepened feelings of loneliness.

Psilocybin experiences fostered a renewed sense of trust and capacity for authentic engagement with others. Participants reported feeling more connected not just during the psychedelic experience itself but in the weeks and months that followed. Being seen, heard, and witnessed — particularly in community or group settings where psilocybin was used — played a significant role in healing. The importance of interpersonal connections was consistently underscored, with several participants noting that the relational dimension of their psilocybin experiences was as therapeutic as the pharmacological effects.

Behaviour Change

Participants reported significant changes in their ability to respond to emotional triggers with greater awareness and patience. Where PMDD had previously hijacked their responses — leading to explosive anger, impulsive decisions, or complete shutdown — psilocybin appeared to create a space between stimulus and response. This "pause" allowed for more conscious choices about how to react.

The practice of self-witnessing — observing one's own emotional states without being consumed by them — was a recurring theme. Participants described moving from reactive, automatic responses to more considered and deliberate engagement with difficult emotions. This enhanced sense of agency and emotional control was particularly meaningful for women who had felt at the mercy of their hormonal cycles for years or decades. The ability to recognise a PMDD-driven impulse and choose not to act on it was described as transformative.

Cultural Considerations

Psilocybin experiences gave participants a broader perspective on their condition within its societal and cultural context. Several women reflected on how PMDD sits at the intersection of gender, medicine, and cultural attitudes toward menstruation and emotional expression. Intergenerational trauma was identified as a significant factor, with participants recognising patterns of emotional suppression and coping that had been passed down through family lines.

A critical theme was the challenge to Western societal norms that pathologize heightened emotional sensitivity. Participants questioned whether the intensity of their emotional experiences during PMDD was entirely pathological or whether it represented a heightened sensitivity that is poorly accommodated by modern Western lifestyles. Psilocybin helped some women reframe their sensitivity not as a deficit but as a quality that required different support structures than contemporary society typically provides.

Discussion

The findings of this exploratory research suggest that psilocybin may be a valuable component in a holistic approach to PMDD management, though it should not be regarded as a panacea. The experiences reported by participants align with broader psychedelic research showing benefits for mood disorders, trauma-related conditions, and emotional regulation — all of which are relevant to the PMDD experience.

The dose-dependent pattern observed in this study is noteworthy. Smaller, moderate doses appeared to provide significant symptom mitigation with less disruption to daily functioning and fewer risks. Larger doses held more transformative potential — including deep trauma processing and lasting perspective shifts — but came with increased risks, particularly when taken without adequate support or preparation. This suggests that a graded approach, potentially starting with moderate doses and moving to larger experiences only with appropriate support, may be advisable.

For some participants, psilocybin facilitated a fundamentally new understanding of and relationship with their PMDD. Rather than viewing the condition purely as pathology to be suppressed, they developed a more nuanced perspective that incorporated self-knowledge, acceptance, and proactive management. This shift in framing — from helpless victim to informed agent — appeared to be as therapeutically significant as any direct symptom reduction. The sense of agency over symptoms, even when they didn't disappear entirely, was consistently reported as life-changing.

Limitations

This study has several important limitations that should be considered when interpreting its findings. Its exploratory nature and broad scope mean that it provides breadth of insight rather than depth on any single aspect of psilocybin use for PMDD. The research was conducted independently and was not institutionally funded, which while preserving independence, also meant limited resources for more rigorous methodological approaches.

Recruitment via social media (Reddit) introduces a self-selection bias, as women who had positive experiences with psilocybin may be more likely to participate and share their stories. The sample size of 11, while appropriate for exploratory qualitative research, cannot support generalizable conclusions. All data was self-reported and retrospective, subject to recall bias and the natural human tendency to construct coherent narratives. Future research should employ prospective designs with objective outcome measures alongside qualitative components.

Future Directions

There is a clear need for more comprehensive, evidence-based research into psilocybin's effects on PMDD. Clinical trials with rigorous methodology — including prospective symptom tracking, placebo controls, and hormonal biomarker assessment — are essential for determining whether the patterns observed in this qualitative research hold up under scientific scrutiny. A balanced and nuanced narrative is needed in the psychedelic space, one that acknowledges both the potential benefits and the real risks of these substances.

Many women are already microdosing psilocybin for PMDD, and formal research is beginning to catch up with grassroots practice. Research is underway at the University of Auckland, led by Suresh Muthukumaraswamy, investigating microdosing for menstrual-related mood disorders. This type of academic engagement with a phenomenon already occurring in the community is precisely what is needed.

Beyond PMDD, other communities of women dealing with hormonally influenced conditions — including PCOS, endometriosis, and perimenopause — could benefit from similar exploratory research. The intersection of psychedelics, hormones, and women's health represents a significant gap in the current research landscape that deserves sustained attention and funding.

Acknowledgements

The author wishes to thank Dr Grace Blest-Hopley (Hystelica) for her expertise and guidance on the neurobiological dimensions of PMDD and psilocybin; Natasha Gukasyan and Sasha Narayan for their thoughtful feedback on methodology and framing; Rachel Sumner for her insights on hormonal mechanisms; Kate Godfred for her editorial review; Tina Williams for her pioneering public writing on PMDD and psilocybin that helped shape the research questions; and Floris Wolswijk for his support in bringing this research to a wider audience through Blossom.

Eleanor Taylor privately invested in this research, making it possible as a fully independent project. Eleanor is based in Lisbon and is the founder of a marketing and data consultancy. Her support exemplifies the kind of private sponsorship that can advance research in areas underserved by traditional funding mechanisms.

References

1. What is PMDD? Premenstrual Dysphoric Disorder. | IAPMD. (n.d.). IAPMD.#
2. ICD-11 for Mortality and Morbidity Statistics. (n.d.). WHO.#
3. Premenstrual Dysphoric Disorder (PMDD). (2023, September 3). PsychDB.#
4. Eisenlohr-Moul, T., Divine, M., Schmalenberger, K., Murphy, L., Buchert, B., et al. (2022). Prevalence of lifetime self-injurious thoughts and behaviors in a global sample of 599 patients reporting prospectively confirmed diagnosis with PMDD. BMC Psychiatry, 22(1), 199.#
5. Epperson, C. N., Steiner, M., Hartlage, S. A., Eriksson, E., Schmidt, P. J., Jones, I., & Yonkers, K. A. (2012). Premenstrual dysphoric disorder: evidence for a new category for DSM-5. American Journal of Psychiatry, 169(5), 465-475.#
6. Yonkers, K. A., O'Brien, P. S., & Eriksson, E. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200-1210.#
7. Osborn, E., Wittkowski, A., Brooks, J., Briggs, P. E., & O'Brien, P. S. (2020). Women's experiences of receiving a diagnosis of premenstrual dysphoric disorder: a qualitative investigation. BMC Women's Health, 20, 1-15.#
8. Steiner, M., Macdougall, M., & Brown, E. (2003). The premenstrual symptoms screening tool (PSST) for clinicians. Archives of Women's Mental Health, 6, 203-209.#
9. Hantsoo, L., Sajid, H., Murphy, L., Buchert, B., Barone, J., Raja, S., & Eisenlohr-Moul, T. (2022). Patient experiences of health care providers in premenstrual dysphoric disorder. Journal of Women's Health, 31(1), 100-109.#
10. Kulkarni, J., Leyden, O., Gavrilidis, E., Thew, C., & Thomas, E. H. (2022). The prevalence of early life trauma in premenstrual dysphoric disorder (PMDD). Psychiatry Research, 308, 114381.#
11. Wittchen, H. U., Perkonigg, A., & Pfister, H. (2003). Trauma and PTSD — An overlooked pathogenic pathway for Premenstrual Dysphoric Disorder? Archives of Women's Mental Health, 6, 293-297.#
12. Sex hormone-sensitive gene complex linked to premenstrual mood disorder. (2017, January 17). ScienceDaily.#
13. Understanding Premenstrual Dysphoric Disorder. (n.d.). SW Londoner.#
14. r/PMDD — Reddit community for PMDD support.#
15. r/PsychedelicWomen — Reddit community for women's psychedelic experiences.#
16. Braun, V., & Clarke, V. (2019). Reflecting on reflexive thematic analysis. Qualitative Research in Sport, Exercise and Health, 11(4), 589-597.#
17. Grey, J. A., & McNaughton, N. (1982). The neuropsychology of anxiety. An enquiry into the functions of the septo-hippocampal system. Oxford Psychology Series. Oxford University Press. (No DOI available.)
18. Kleinstäuber, M., Schmelzer, K., Ditzen, B., Andersson, G., Hiller, W., & Weise, C. (2016). Psychosocial profile of women with premenstrual syndrome and healthy controls. International Journal of Behavioral Medicine, 23, 752-763.#
19. Williams, T. (2023, March 30). Psilocybin and PMDD. The Woman in the Basement.#
20. Kim, D. R., Gyulai, L., Freeman, E. W., Morrison, M. F., Baldassano, C., & Dube, B. (2004). Premenstrual dysphoric disorder and psychiatric co-morbidity. Archives of Women's Mental Health, 7, 37-47.#